# Deep-immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.

Authors

Koji Nagaoka, Masataka Shirai, Kiyomi Taniguchi, Akihiro Hosoi, Changbo Sun, Yukari Kobayashi, Kazuhiro Maejima, Masashi Fujita, Hidewaki Nakagawa, Sachiyo Nomura and Kazuhiro Kakimi

Correspondence

kakimi@m.u-tokyo.ac.jp,

In Brief

Deep phenotyping of YTN16 tumors identified a sequence of events on the axis CCL20→IL-17-producing cells → IL-17 → neutrophil → angiogenesis and suppression of neoantigen-specific CD8+ T cells which was responsible for the lack of tumor rejection.